Results 291 to 300 of about 1,859,821 (399)

A Quantitative Imaging Measure of Progressive Pulmonary Fibrosis. [PDF]

Am J Respir Crit Care Med
Wang JM, Adegunsoye A, Pugashetti JV, Lee CT, Murray S, Mohan N, Nazemi N, Kang E, Chelala L, Kazerooni EA, Flaherty KR, Belloli EA, Sheth JS, O'Dwyer DN, Strek ME, Hatt CR, Han MK, Chung JH, Oldham JM.   +18 more
europepmc   +1 more source

A Volumetric Computed Tomography Analysis of the Normal Lung in Idiopathic Pulmonary Fibrosis: The Relationship with the Survival

, 2017
Hirotsugu Ohkubo, Hiroyuki Taniguchi, Yasuhiro Kondoh, Mitsuaki Yagi, Taiki Furukawa, Takeshi Johkoh, Hiroaki Arakawa, Junya Fukuoka, Akio Niimi   +8 more
openalex   +2 more sources

Linezolid prevents fibroblast activation and ameliorates tissue fibrosis by inhibition of mitochondrial translation

Arthritis &Rheumatology, Accepted Article.
Background Beyond its role as a ribosome‐targeting antibiotic, linezolid was recently shown to modulate immune responses by inhibiting mitochondrial translation. Since mitochondrial dysfunction is implicated in various fibrotic diseases, including systemic sclerosis (SSc), this study aimed to evaluate the antifibrotic potential of linezolid and ...
Xuezhi Hong, Yanhua Xiao, Haodong Qi, Shihao Zhu, Tim Filla, Andrea‐Hermina Györfi, Yi‐Nan Li, Meilin Xu, Langxian Zhi, Thuong Trinh‐Minh, Clara Dees, Georg Schett, Jörg H.W. Distler, Alexandru‐Emil Matei   +13 more
wiley   +1 more source

Procyanidin C1 inhibits bleomycin‐induced pulmonary fibrosis in mice by selective clearance of senescent myofibroblasts [PDF]

Min Shao, Yujia Qiu, Mengxia Shen, Wei Liu, Dandan Feng, Ziqiang Luo, Yan Zhou   +6 more
openalex   +1 more source

A cooperative release of mitochondrial DNA from platelets and neutrophils drives an interferon signature in systemic sclerosis

Arthritis &Rheumatology, Accepted Article.
Objective Mitochondria are organelles with a hypomethylated circular genome. Mitochondrial DNA (mtDNA) in the systemic circulation has been implicated in inflammation. This study investigates the role of circulating DNA in systemic sclerosis (SSc) and the cellular mechanisms governing its release.
Stavros Giaglis, André N. Tiaden, Simone Häner‐Massimi, Diego Kyburz, Cedric André, Anton Glück, Enrico Ferrero, Stuart Hawtin, Tobias Junt, Ulrich A. Walker   +9 more
wiley   +1 more source

Osteoprotegerin Is Elevated in Pulmonary Fibrosis and Associates with Idiopathic Pulmonary Fibrosis Progression: A Pilot Study.

Respiration
Habibie H, Putri KSS, Boorsma CE, Brass DM, Heukels P, Wijsenbeek M, Kool M, van den Berge M, Borghuis T, Vaughan A, Corte T, Liu G, Brandsma CA, Gan CT, Olinga P, Timens W, Kahn N, Hansbro PM, Kreuter M, Burgess JK, Melgert BN.   +20 more
europepmc   +1 more source

Extracellular matrix anchored neutrophils drive pulmonary fibrosis in mice. [PDF]

Nat Commun
Yang L, Sun P, Wang J, Xu M, Zhu B, Yu K, Rong Y, Mao R, Zi S, Liu C, Huang J, Ma J, Chen H, Luo W, Zhang W, Zhang X, Fang S, Chao J.   +17 more
europepmc   +1 more source

Long‐Term Outcomes of Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Systemic Sclerosis Patients with Impaired Cardiac Function

Arthritis &Rheumatology, Accepted Article.
Objective High intensity conditioning autologous hematopoietic stem cell transplantation (AHSCT) is standard of care for patients with advanced SSc. The role of reduced intensity conditioning (RIC) prior to AHSCT in this population remains unclear. We conducted this study to determine the long‐term outcomes of RIC AHSCT in SSc patients with cardiac ...
Yonatan Lean, Carrie Richardson, Anthony Esposito, Katy Bedjeti, George E. Georges   +4 more
wiley   +1 more source

Aggravated effects of human parvovirus B19 NS1 protein on bleomycin‑induced pulmonary fibrosis. [PDF]

Mol Med Rep
Hsu TC, Tzang CC, Kuo CW, Wen ZH, Chen DY, Tzang BS.   +5 more
europepmc   +1 more source

Impact of evolving treatment patterns on interstitial lung disease progression in systemic sclerosis using the EUSTAR database

Arthritis &Rheumatology, Accepted Article.
Background The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasing immunosuppressive (IST) and anti‐fibrotic therapies available. However, their real‐world use remains unclear. Objectives To analyze treatment trends and the effect of IST and anti‐fibrotic therapies on ILD progression ...
Corrado Campochiaro, Marie‐Elise Truchetet, Madelon Vonk, Giacomo De Luca, Giovanna Cuomo, Lidia P. Ananieva, Eric Hachulla, Vanessa Smith, Ana Maria Gheorghiu, Radim Becvar, Patricia Carreira, Nicolas Hunzelmann, Daniel E. Furst, Vera Ortiz‐Santamaria, Francesco Del Galdo, Marco Matucci‐Cerinic, Anna‐Maria Hoffmann‐Vold, EUSTAR collaborators   +17 more
wiley   +1 more source